1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Pipeline Review, H2 2020, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.
Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 23, 204, 192, 3, 6, 132, 31 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 12, 12, 1, 21, 4 and 1 molecules, respectively.
Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Head And Neck Cancer - Overview
- Head And Neck Cancer - Therapeutics Development
- Head And Neck Cancer - Therapeutics Assessment
- Head And Neck Cancer - Companies Involved in Therapeutics Development
- Head And Neck Cancer - Drug Profiles
- Head And Neck Cancer - Dormant Projects
- Head And Neck Cancer - Discontinued Products
- Head And Neck Cancer - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Head And Neck Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Head And Neck Cancer - Pipeline by 2A Pharma AB, H2 2020
- Head And Neck Cancer - Pipeline by 4D Pharma Plc, H2 2020
- Head And Neck Cancer - Pipeline by 4SC AG, H2 2020
- Head And Neck Cancer - Pipeline by A2 Biotherapeutics Inc, H2 2020
- Head And Neck Cancer - Pipeline by Aadi Bioscience Inc, H2 2020
- Head And Neck Cancer - Pipeline by ABBA Therapeutics AG, H2 2020
- Head And Neck Cancer - Pipeline by AbbVie Inc, H2 2020
- Head And Neck Cancer - Pipeline by Abion Inc, H2 2020
- Head And Neck Cancer - Pipeline by Lycera Corp, H2 2020
List of Figures
- Number of Products under Development for Head And Neck Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2A Pharma AB
- 4D Pharma Plc
- 4SC AG
- A2 Biotherapeutics Inc
- Aadi Bioscience Inc
- ABBA Therapeutics AG
- AbbVie Inc
- Abion Inc
- ABL Bio Inc
- Acepodia Biotech Inc
- Adaptimmune Therapeutics Plc
- ADC Therapeutics SA
- Adlai Nortye Biopharma Co Ltd
- Advanced Accelerator Applications SA
- Advaxis Inc
- Advenchen Laboratories LLC
- Adze Biotechnology Inc
- Affimed GmbH
- Agenus Inc
- Akeso Inc
- Alkermes Plc
- Alligator Bioscience AB
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- Aura Biosciences Inc
- Aurigene Discovery Technologies Ltd
- Avalon GloboCare Corp
- AVEO Pharmaceuticals Inc
- Aveta Biomics Inc
- Avvinity Therapeutics Ltd
- Bavarian Nordic A/S
- Bayer AG
- BeiGene Ltd
- CarboMimetics
- Cardiff Oncology Inc
- CEL-SCI Corp
- Celldex Therapeutics Inc
- Cellectar Biosciences Inc
- Cello Therapeutics Inc
- Celprogen Inc
- Centurion BioPharma Corp
- Checkmate Pharmaceuticals Inc
- Checkpoint Therapeutics Inc
- Chengdu Wonho Biology Engineering Co Ltd
- Chi Cheung (Shanghai) Biomedical Co Ltd
- China Immunotech Co Ltd
- Etubics Corp
- Eutilex Co Ltd
- Immvira Co Ltd
- Imugene Ltd
- IMV Inc
- Incyte Corp
- Infinity Pharmaceuticals Inc
- Inhibrx Inc
- Innate Pharma SA
- Innovene
- Innovent Biologics Inc
- Inovio Pharmaceuticals Inc
- Intensity Therapeutics Inc
- InteRNA Technologies BV
- Invectys SA
- InxMed Shanghai Co Ltd
- IO Biotech ApS
- Iovance Biotherapeutics Inc
- Ipsen SA
- ISA Pharmaceuticals BV
- iSTAT Therapeutics Inc
- ISU ABXIS Co Ltd
- Jacobio Pharmaceuticals Group Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- Jiangsu Vcare PharmaTech Co Ltd
- Johnson & Johnson
- Jounce Therapeutics Inc
- Juno Therapeutics Inc
- Kintara Therapeutics Inc
- Kitov Pharma Ltd
- Komipharm International Co Ltd
- Kuur Therapeutics Ltd
- Kymab Ltd
- Kyowa Kirin Co Ltd
- L.E.A.F. Pharmaceuticals LLC
- Laboratoires Pierre Fabre SA
- LATITUDE Pharmaceuticals Inc
- Leucid Bio Ltd
- LIfT BioSciences Ltd
- LightOx Ltd
- Lion TCR Pte Ltd
- LipoSeuticals Inc
- Luminus Biosciences Inc
- Luye Pharma Group Ltd
- Luzitin SA
- Lycera Corp
- LynkCell Inc
- Lytix Biopharma AS
- Mabion SA
- Mabpharm Ltd
- MacroGenics Inc
- MAIA Biotechnology Inc
- Mateon Therapeutics Inc
- Maverick Therapeutics Inc
- MaxiVAX SA
- MediciNova Inc
- Medivir AB
- Merck & Co Inc
- Merck KGaA
- Mereo Biopharma Group Plc
- Mersana Therapeutics Inc
- Metaclipse Therapeutics Corp
- Millennium Pharmaceuticals Inc
- Mirati Therapeutics Inc
- MiRecule Inc
- MiReven Pty Ltd
- Mitsubishi Tanabe Pharma Corp
- Moderna Inc
- Modra Pharmaceuticals BV
- Molecular Partners AG
- Molecular Templates Inc
- Moleculin Biotech Inc
- MolMed SpA
- MultiVir Inc
- Nanjing Iaso Biotherapeutics Co Ltd
- NanoCarrier Co Ltd
- NantBioScience Inc
- NantKwest Inc
- Natco Pharma Ltd
- Nektar Therapeutics
- Neonc Technologies Inc
- NeoTX Therapeutics Ltd
- Neumedicines Inc
- NextCure Inc
- NGM Biopharmaceuticals Inc
- Northwest Biotherapeutics Inc
- Novartis AG
- Noxopharm Ltd
- Nubiyota LLC
- Numab Therapeutics AG
- Ocellaris Pharma Inc
- Ona Therapeutics SL
- OncoImmune Inc
- Oncolys BioPharma Inc
- Onconova Therapeutics Inc
- Oncorus Inc
- OncoSec Medical Inc
- Oncovir Inc
- OncXerna Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Onxeo SA
- Otsuka Holdings Co Ltd
- Ovensa Inc
- Oxford Vacmedix UK Ltd
- PDS Biotechnology Corp
- Pfizer Inc
- Pharma Mar SA
- Philogen SpA
- Phio Pharmaceuticals Corp
- Phosplatin Therapeutics LLC
- PIQUR Therapeutics AG
- Plexxikon Inc
- Plus Therapeutics Inc
- PNP Therapeutics Inc
- Polaris Pharmaceuticals Inc
- Potenza Therapeutics Inc
- Precigen Inc
- PRISM Pharma Co Ltd
- Privo Technologies Inc
- Protheragen Inc
- PsiOxus Therapeutics Ltd
- Psivac Ltd
- QBiotics Ltd
- Qilu Pharmaceutical Co Ltd
- Qilu Puget Sound Biotherapeutics Corp
- Qrono Inc
- Quadriga BioSciences Inc
- R Pharm
- Rakuten Medical Inc
- RAPT Therapeutics Inc
- RaQualia Pharma Inc
- Refuge Biotechnologies Inc
- Regeneron Pharmaceuticals Inc
- Reven Pharmaceuticals Inc
- Sanofi
- Sareum Holdings Plc
- Scancell Holdings Plc
- Seagen Inc
- Secura Bio Inc
- SEEKYO Therapeutics
- Sensei Biotherapeutics Inc
- Seven and Eight Biopharmaceuticals Corp
- Shanghai GeneChem Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai Jing Ze Biotechnology Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Miracogen Inc
- Shattuck Labs Inc
- Shionogi & Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- Sino Biopharmaceutical Ltd
- Sirnaomics Inc
- Sirona Therapeutics Inc
- SL Bigen Inc
- Smerud Medical Research International AS
- SMET Pharmaceutical Inc
- Sonnet BioTherapeutics Holdings Inc
- Soricimed Biopharma Inc
- Sotio AS
- Spring Bank Pharmaceuticals Inc
- SQZ Biotechnologies Co
- STAT3 Therapeutics Inc
- Stcube Inc
- Stella Pharmaceuticals Pvt Ltd
- Sumitomo Dainippon Pharma Co Ltd
- Sumitomo Dainippon Pharma Oncology, Inc
- SuviCa Inc
- Suzhou Max Bio-tech Co Ltd
- Suzhou Neupharma Co Ltd
- Suzhou Zanrong Pharmaceutical Technology Co Ltd
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Sveikatal Inc
- Synermore Biologics Co Ltd
- Syntrix Biosystems Inc
- Systimmune Inc
- Tactical Therapeutics Inc
- TAE Life Sciences LLC
- Takis Srl
- Tallikut Pharmaceuticals Inc
- TCR Cure Biopharma Technology Co Ltd
- Telix Pharmaceuticals Ltd
- Tempest Therapeutics Inc
- Tessa Therapeutics Ltd
- Tevogen Bio Inc
- Theralase Technologies Inc
- Theravectys SA
- TOLREMO Therapeutics AG
- Torque Therapeutics Inc
- TOT Biopharm Co Ltd
- Touchlight Genetics Ltd
- Transgene SA
- Treadwell Therapeutics Inc
- Turning Point Therapeutics Inc
- Turnstone Biologics Inc
- Tvardi Therapeutics Inc
- Tyme Technologies Inc
- UbiVac LLC
- Vaccibody AS
- Vaccinex Inc
- VasGene Therapeutics Inc
- Vault Pharma Inc
- VCN Biosciences SL
- Vectorite Biomedical Inc
- Venus Remedies Ltd
- Viracta Therapeutics Inc
- Viralytics Pty Ltd
- Virion Therapeutics LLC
- Virocure Inc
- VM Discovery Inc
- Voronoi Group
- Vyriad Inc
- Wayshine Biopharma Inc
- WindMIL Therapeutics Inc
- Wuhan Binhui Biotechnology Co Ltd
- Xbrane Biopharma AB
- Xencor Inc
- Xiangxue Life Sciences
- XuanZhu Pharma Co Ltd
- Xynomic Pharmaceuticals Holdings Inc
- Zhejiang Yangshengtang Biotech Co Ltd
- Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
- Zymeworks Inc
